Related Experiment Video

Updated: Aug 16, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

[Proteasome inhibitors]

J Alexandre1

  • 1Service de médecine interne, unité d'oncologie médicale, groupe hospitalier Cochin-Saint-Vincent-de-Paul, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France. jerome.alexandre@cch.ap-hop-paris.fr

La Revue De Medecine Interne
|September 1, 2005
PubMed
Abstract

Insights

Proteasome inhibition, using bortezomib, shows promise in treating lymphoid cancers. While effective in some blood cancers, its use in solid tumors is limited by side effects, but it may enhance other cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The proteasome regulates cell cycle and apoptosis, and its dysregulation is implicated in cancer development.
  • Bortezomib, a proteasome inhibitor, is approved for multiple myeloma and mantle cell lymphoma.
  • Adverse events like neurotoxicity can limit bortezomib's long-term application.

Purpose of the Study:

  • To review the role of proteasome inhibition in cancer therapy.
  • To discuss the efficacy and limitations of bortezomib.
  • To explore potential combination strategies involving bortezomib.

Main Methods:

  • Review of preclinical data and clinical trial outcomes for bortezomib.
  • Analysis of proteasome function in cell cycle and apoptosis.
  • Evaluation of bortezomib's therapeutic effects and adverse events.

Main Results:

  • Bortezomib demonstrates significant antitumor activity in multiple myeloma and mantle cell lymphoma.
  • Modest efficacy of bortezomib as a single agent in solid tumors.
  • Preclinical evidence suggests bortezomib can potentiate the activity of cytotoxic agents.

Conclusions:

  • Proteasome inhibition represents a viable therapeutic strategy, particularly for hematologic malignancies.
  • Further research is warranted to optimize bortezomib use and overcome limitations in solid tumors.
  • Combination therapies may enhance the clinical utility of proteasome inhibitors.

More Related Videos

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Related Concept Videos

The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome Structure01:17

The Proteasome Structure

The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...